Skip to main content

Advertisement

SpringerLink
Log in

Certolizumab Pegol for Psoriasis and Psoriatic Arthritis

  • Psoriasis (J Wu, Section Editor)
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The purpose of this review is to provide an overview of the use of certolizumab pegol (Cimzia®, UCB S.A.) for psoriasis and psoriatic arthritis and summarize important findings.

Recent Findings

Three pivotal phase three clinical trials CIMPASI-1, CIMPASI-2, and CIMPACT have demonstrated efficacy and safety of certolizumab pegol (CZP) in patients with plaque psoriasis. In addition, another multicenter phase three clinical trial, RAPID-PsA, has shown long-term efficacy and safety data of CZP in psoriatic arthritis.

Summary

When compared with other TNF-alpha blockers, CZP has demonstrated increased efficacy in psoriasis. In addition, CZP has also shown clinically significant and sustained improvement in psoriatic arthritis based on symptoms and radiographic evidence in patients with up to 4 years of follow-up. The safety profile of CZP is comparable to other anti-TNF agents. Finally, CZP’s unique structure as a PEGylated monoclonal antibody fragment prevents placental transfer and therefore may make it an ideal choice as a biologic medication for women of childbearing age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005;175(4):2721–9.

    Article  CAS  Google Scholar 

  2. Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs. 2014;28(1):15–23.

    Article  Google Scholar 

  3. Weir ANC, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson ADG. Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc Trans. 2002;30(4):512–6.

    Article  CAS  Google Scholar 

  4. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis. 2007;13(11):1323–32.

    Article  Google Scholar 

  5. Tun GS, Lobo AJ. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn’s disease. Expert Opin Drug Metab Toxicol. 2015;11(2):317–27.

    Article  CAS  Google Scholar 

  6. cimzia-epar-refusal-public-assessment-report_en.pdf [Internet]. [cited 2019 Oct 13]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/cimzia-epar-refusal-public-assessment-report_en.pdf

  7. CIMZIA_full_prescribing_information.pdf [Internet]. [cited 2019 Oct 11]. Available from: https://www.cimzia.com/themes/custom/cimzia/docs/CIMZIA_full_prescribing_information.pdf

  8. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008 Sep 1;22(5):315–29.

    Article  CAS  Google Scholar 

  9. •• Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79(2):302–314.e6 Key phase three CZP trial for plaque psoriasis.

    Article  CAS  Google Scholar 

  10. •• Lebwohl M, Blauvelt A, Paul C, Sofen H, Węgłowska J, Piguet V, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79(2):266–276.e5 Key phase three CZP trial for plaque psoriasis.

    Article  CAS  Google Scholar 

  11. • Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, et al. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. J Eur Acad Dermatol Venereol. 2019;33(3):546–52 Provides pooled data from key phase three CZP clinical trials for psoriasis.

    Article  CAS  Google Scholar 

  12. Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev [Internet]. 2017 Dec 22 [cited 2019 Oct 14];2017(12). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486272/

  13. Reich K, Ortonne J-P, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180–90.

    Article  CAS  Google Scholar 

  14. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72(4):517–24.

    Article  CAS  Google Scholar 

  15. Kerensky TA, Gottlieb AB, Yaniv S, Au S. Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf. 2012;11(1):121–39.

    Article  CAS  Google Scholar 

  16. Nast A, Jacobs A, Rosumeck S, Werner RN. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2015;135(11):2641–8.

    Article  CAS  Google Scholar 

  17. Curtis JR, Mariette X, Gaujoux-Viala C, Blauvelt A, Kvien TK, Sandborn WJ, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019;5(1):e000942.

    Article  Google Scholar 

  18. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385–90.

    Article  CAS  Google Scholar 

  19. •• van der Heijde D, Deodhar A, FitzGerald O, Fleischmann R, Gladman D, Gottlieb AB, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open. 2018;4(1):e000582 Key phase three CZP trial for psoriatic arthritis.

    Article  Google Scholar 

  20. Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clin Rheumatol. 2018 Dec 1;37(12):3285–96.

    Article  CAS  Google Scholar 

  21. Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczyński P, et al. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open. 2015;1(1):e000119.

    Article  CAS  Google Scholar 

  22. Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol. 2005;141(5):601–6.

    Article  CAS  Google Scholar 

  23. Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo R-M, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–33.

    Article  CAS  Google Scholar 

  24. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti–tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286–92.

    Article  CAS  Google Scholar 

  25. Clowse ME, Förger F, Hwang C, Thorp J, Dolhain RJ, van Tubergen A, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890–6.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of California San Francisco, 515 Spruce Street, San Francisco, CA, 94118, USA

    Vidhatha Reddy, Quinn Thibodeaux & John Koo

Authors
  1. Vidhatha Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Quinn Thibodeaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Koo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vidhatha Reddy.

Ethics declarations

Conflict of Interest

Dr. John Koo is on the Speaker’s Bureau for UCB and serves as an advisor. Drs. Vidhatha Reddy and Quinn Thibodeaux declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Psoriasis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reddy, V., Thibodeaux, Q. & Koo, J. Certolizumab Pegol for Psoriasis and Psoriatic Arthritis. Curr Derm Rep 9, 100–106 (2020). https://doi.org/10.1007/s13671-020-00298-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-020-00298-y

Keywords

Search

Navigation